Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome: A Patient Guide

Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome is a descriptive multisystem phenotype that belongs to a group of disorders known as Telomere Biology Disorders (TBDs) or Short Telomere Syndromes ^[1]. At its core, the condition involves the premature wearing away of telomeres, the protective caps on the ends of your DNA ^[2]. When these caps become too short, the cells in your body can no longer repair themselves or divide properly. This leads to a form of cellular senescence that primarily affects organs requiring frequent cell turnover: the lungs, the liver, and the bone marrow.

This guide is educational. Because pulmonary fibrosis, liver disease, and bone marrow hypoplasia can all have other separate causes, your exact diagnosis, organ involvement, and treatment plan must be confirmed by a TBD-experienced specialist team ^[3].

Unlike the childhood forms of telomere disorders, adult-onset versions frequently lack the “classic” outward signs like skin changes or nail issues, which can make the diagnosis difficult to reach ^[4]. Instead, the condition typically reveals itself through internal changes. These can include scarring in the lungs (pulmonary fibrosis), unusual vascular or growth patterns in the liver (hepatic hyperplasia), and a decline in the bone marrow’s ability to produce healthy blood cells ^[3].

Because the syndrome spans three distinct medical specialties, management requires a highly coordinated, multidisciplinary care team ^[5]. No single organ can be treated in isolation. For example, the health of the liver can directly impact the oxygen levels in the lungs, and the fragility of the bone marrow must be carefully considered before starting any intensive treatments or surgeries ^[6]. This interconnectedness is why specialized monitoring and a unified treatment plan are essential.

The approach to treatment is focused on slowing the progression of organ damage and protecting the body’s regenerative capacity. This may include the use of off-label medications to manage lung scarring and hormonal support to help the bone marrow ^[7]. If the condition progresses to the point where a hematopoietic stem cell transplant becomes necessary, it is often performed using specialized, “reduced-intensity” protocols designed to protect your fragile organs from the toxicities of standard transplant conditioning ^[8]. Solid organ transplants (lung or liver) require their own organ-specific surgical and immunosuppressive adjustments ^[9].

Navigating this diagnosis means becoming an expert in your own health and building a partnership with a medical team that understands short telomere biology. While the condition is serious and complex, a proactive approach to monitoring allows you and your care team to focus on preservation, support, and long-term coordination ^[7].